The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
TR1 - Major Holdings Notification
Name
Jonathan Mark Swann
City of registered office (if applicable)
rickmansworth
Country of registered office (if applicable)
United Kingdom
RNS Number : 6661H
Genflow Biosciences PLC
21 March 2024
21 March 2024
Genflow Biosciences Plc
Announces Publication of a Key European Patent in Partnership with University of Rochester, New York, et al.
Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) ("Genflow" or "the Company"), an emerging leader in the field of longevity research, focused on developing therapeutic solutions for the prevention of age-related diseases, is pleased to announce a significant milestone in its journey. Genflow's collaborative partners, including the University of Rochester, The Trustees of Columbia University in the City of New York, and Albert Einstein College of Medicine, have received confirmation that their European patent application was published today by the European Patent Office, bearing the reference number EP 4 338 267.
Innovation in Age-Related Disease Prevention and Treatment
The patent, titled "Variants of SIRT6 for Use in Preventing and/or Treating Age-Related Diseases," enhances the understanding and potential treatment of diseases associated with aging by focusing on the SIRT6 gene/protein, known for its critical role in DNA repair, metabolism, and longevity.
SIRT6 regulates DNA damage repair, specifically double strand breaks (DSB) and prevents or delays aging of cells. Genflow's lead drug candidate, GF-1002, delivers a centenarian variant of the SIRT6 gene. Genflow is currently undertaking key Investigational New Drug (IND)-enabling development activities that will help define the pharmacological and toxicological properties of GF-1002 and its potential benefits, initially, for non-alcoholic steatohepatitis (NASH) patients.
In 2023, the Company received positive feedback from the Federal Agency for Medicines and Health Products in Belgium and expects a follow-up meeting in Q2 2024 to finalise design of Phase/II clinical trials. NASH, the most severe form of non-alcoholic fatty liver disease (NAFLD) characterized by excessive fat deposits in the liver, is usually a silent disease with few, if any, symptoms, and effective treatments.
Dr. Eric Leire, CEO of Genflow commented: "This approval from the European Patent Office highlights the innovative spirit of our collaborative team and we are incredibly proud to be part of this pioneering research alongside such respected institutions." He continued, "This patent represents a leap forward in our understanding and capabilities in treating age-related conditions and marks a significant step forward in our mission to develop effective therapies for NASH and other age-related diseases."
Yep, he also hinted at institutional investors which would make all the difference to current sp performance. Gl ;-)
Eric's presentation. Gla ;-)
Genflow Biosciences Plc (OTCQB: GENFF | LSE: GENF): Virtual Investor Conferences
hTtps://www.youtube.com/watch?v=0ZhaxbymGk4
Yes indeed Porter, I was thinking we could get news before the presentation anytime from Monday morning, maybe that's why Eric has the first slot!!!??? Gl:-)
Ps Northeast, and how great would it be if Eric's presentation was backed up by some stellar news from Vera and Co from the crucial invivo studies which were expected end of 2023.....looking forward to this coming week.....Gl ;-)
Nice one Northeast, and Genflow are first to present. Gl ;-)
hTtps://www.virtualinvestorconferences.com/events/event-details/life-science-investor-forum-2
Genflow Biosciences (LON:GENF) (OTCQB:GENFF)
1,475 followers
4h
We here at Genflow Biosciences (LON:GENF) (OTCQB:GENFF) are proud of the accomplishments we’ve made in 2023 and look forward to an even more prosperous 2024.
We’d like to share our Year-End Review with you, as well as what we are most excited for in the upcoming year: htTps://loom.ly/Y_dqlDw
#healthspan #longevity
Genflow Biosciences (LON:GENF) (OTCQB:GENFF)
1,475 followers
4h
Genflow Biosciences (LON:GENF) (OTCQB:GENFF) was thrilled to hear that Ely Lilly was successful achieving pharmacologic restoration of hearing in a boy with profound congenital hearing loss. This story highlights joint importance of academic innovation, entrepreneurship, early stage venture capital and large #pharma acquisitions and investment
Read more about the exciting development here: hTtps://loom.ly/6e6rByY
#longevity #healthspan #biosciences
R&D results expected imminently from University of Rochester , and no doubt Genflow’s other 3 collaborators conducting in-vivo studies on Genflow’s AAV delivery system for Sirt6, positive results according to Vera will be "powerful" for Sirt6 to translate to human clinical trials, which in turn could be the catalyst for some major interest and major investment imho...Gla :-)
A must listen!!!
htTps://www.listennotes.com/podcasts/modern-healthspan/sirt6-the-science-behind-the-Z8u9qApmey_/
A compelling, insightful and exciting podcast on Sirt6's strong and promising potential and influence in longevity and multiple disease targets, with study results expected soon. Gla :-)
Podcast interview with Vera Gorbunova from 24/10/2÷ discussing the promising potential for Sirt6 and how she is conducting research in collaboration with Biotech companies, and confirms results should be available in a few months. Gla :-)
SIRT6 The Science Behind The Longevity Gene | Professor Vera Gorbunova Ep1
Oct. 24, 2023
htTps://www.listennotes.com/podcasts/modern-healthspan/sirt6-the-science-behind-the-Z8u9qApmey_/
GenFlow Biosciences partnership with Revatis SA and EXO Biologics in Groundbreaking Aging Research, Fueled by Two Major Research Grants 🧬
View organization page for Revatis
Revatis
659 followers
1mo
An excellent start to 2024: our intellectual property is strengthened by the granting of a patent in South Korea, very useful for our tissue engineering projects. #tissueengineering #stemcells #regenerativemedicine #celltherapy #cellandgenetherapy
Updates
View organization page for Revatis
Revatis
659 followers
16h
In Australia, too, our intellectual property rights have been strengthened by the granting of this new patent covering new uses for our technology.
hTtps://www.linkedin.com/company/revatis
EXO Biologics
2,052 followers
3d
📢 Press Release: ExoXpert Launched by EXO Biologics to Meet Global Exosome Demand.
We are thrilled to announce the worldwide launch of ExoXpert, a cutting-edge contract development and manufacturing organization (CDMO) by EXO Biologics . ExoXpert, with the ExoPulse, platform is dedicated to addressing the increasing demand for exosomes in the biopharmaceutical industry.
"Our vision for ExoXpert is to provide specialized exosome manufacturing capabilities to meet the increasing needs of the market," stated Romain du Hecquet de Rauville, Chief Business Officer at EXO Biologics. "With the launch of ExoXpert, we aim to make a significant contribution to the advancement of exosome-based therapies."
🌐 ExoXpert's Key Features:
🚀 The ExoPulseTM manufacturing platform, designed by EXO Biologics and used in clinical trial, to provide clients a fast-track access to clinic.
🚀 R&D exosome vials on demand
🚀 State-of-the-art exosome manufacturing plant with Grade A/B and C clean rooms.
🚀 Specialized staff and management committed to quality and innovation.
"I'm proud to witness ExoXpert's launch," said Hugues Wallemacq, CEO of EXO Biologics. "This initiative not only tackles the hurdles in exosome production and characterization but also propels the advancement of exosome-based therapeutics on a global scale."
hTps://be.linkedin.com/company/exo-biologics
Link to Full Press Release: htTps://lnkd.in/d-btKWJR
· Develop and implement project management, budgeting and governance for collaborative partners, in line with clinical and pre-clinal activities that will enable IND applications.
· Moving key patent applications under the Patent Cooperation Treaty (PCT) to the national phase, while further expanding our development pipeline with new products and new indications.
Dr. Eric Leire, CEO of Genflow commented: "The milestones we reached in 2023 were numerous, and I commend our team for their exceptional commitment to execution and delivery. While 2023 was a pivotal year, we're poised for an even stronger 2024, as we shift focus to scaling development of our lead drug candidate, GF-1002, and its potential benefits for NASH patients. With the support of our partners and the backing of new grants, we are poised to make meaningful advancements in the field of longevity."
RNS Number : 4088B
Genflow Biosciences PLC
01 February 2024
1 February 2024
Genflow Biosciences Plc
("Genflow" or "the Company")
Genflow Biosciences Releases 2023 Year-End Review and Highlights Key Priorities for 2024
The Company (LSE:GNF) (OTCQB:GENFF), an emerging leader in the field of longevity research developing therapeutics that potentially halt or slow the ageing process, is pleased to provide a year-end review and summary of its progress during 2023 and defined strategic priorities for 2024.
The Company achieved many significant accomplishments throughout the year across all aspects of its business. The full year-end review can be viewed on Genflow's website: https://genflowbio.com/genflow-biosciences-plc-2023-year-in-review/.
Key 2023 Highlights:
· Genflow expanded its intellectual property portfolio with a provisional patent application for editing the SIRT6 gene, linked to longevity and age-related diseases.
· Began trading on the OTCQB Venture Market in the US under the ticker GENFF, aligned to its US-focused strategy.
· Genflow received positive feedback from the Federal Agency for Medicines and Health Products in Belgium on the design of Phase I/II clinical trials for its lead drug candidate, GF-1002, in NASH patients.
· Genflow made several key appointments, including Capital Plus Partners Ltd as Joint Broker in order to access both institutional and international investment; Harbor Access for investor relations support; and Prof. Dr. Sven Francque, an expert in nonalcoholic fatty liver disease and Prof. Dr. Mary E. Rinella, a fatty liver disease specialist to its Scientific Advisory Board.
Strategic Priorities in 2024:
· Genflow awarded 2.89 million Euros in two new grants that will broaden its research pipeline and expand the size of its therapeutic markets over the next three years. (Refer to press release: https://www.globenewswire.com/news-release/2024/01/18/2811445/0/en/Genflow-Biosciences-Partners-with-Revatis-SA-and-EXO-Biologics-in-Groundbreaking-Aging-Research-Fueled-by-Two-Major-Research-Grants.html)
· Genflow to undertake key Investigational New Drug (IND)-enabling development activities that will help define the pharmacological and toxicological properties of its lead drug candidate, GF-1002, and its potential benefits for NASH patients.
· Initial site selection and QMS framework for clinical readiness, expected by the end of 2025 for the NASH program.
· Commence preliminary discussions with the European Medicines Agency (EMA) on Mechanism of Action (MoA) data for Orphan Drug Application (ODA) for our second compound GF-3001, targeting Werner Syndrome.
· Select Contract Development and Manufacturing Organization (CDMO) for advancing the GMP manufacturing of the NASH clinical lot of lead drug candidate, GF-1002.
· Develop and implement pr
Too many punters have sold their shares too cheaply, me thinks...Gla holders...On and UP!!! :-)
Genflow Biosciences PLC (LSE:GENF, OTCQB:GENFF) chief executive officer Dr. Eric Leire spoke with Proactive's Stephen Gunnion to discuss the impact of two substantial research grants awarded to Genflow in Belgium.
These grants are not just financial boons but are fostering critical collaborations in the field of advanced therapy medicinal products (ATMPs), marking a new era in biotechnological research and development.
Stephen Gunnion (SG): Dr. Leire, can you elaborate on the scope of these grants and their importance for Genflow Biosciences?
Eric Leire (EL): These grants are a major milestone for us. They primarily focus on enhancing collaborations in advanced therapy medicinal products, or ATMPs. Specifically, they support our partnerships with EXO Biologics for exosome manufacturing and Revatis SA for sarcopenia research. Sarcopenia, the age-related muscle loss condition, is a critical research area for Genflow. The grants cover 80% of the project costs, which is substantial financial backing, allowing us to enhance our research capabilities significantly.
SG: Could you shed some light on how these collaborations align with Genflow’s broader strategic goals?
EL: Absolutely. These collaborations are integral to our three-year plan of building a robust biotech ecosystem in Belgium. By working closely with academic centres and various biotech actors, we aim to significantly bolster our research capabilities. This not only enhances our company valuation through meaningful milestones but also strengthens our position in the biotech market by increasing shareholder value and validating the scientific rigour of our research.
SG: With such a focused approach towards ATMPs and age-related diseases, what are the long-term implications for Genflow's research portfolio?
EL: Our long-term vision is to expand our pipeline, focusing on gene therapy and age-related diseases. This strategy is designed to mitigate financial and scientific risks in the challenging biotech market. By diversifying and strengthening our research portfolio, we aim to establish Genflow as a leader in biotech innovation, particularly in the field of longevity and age-related conditions.
SG: Finally, what are the future plans for Genflow in terms of collaborations and research directions?
EL: Looking ahead, we are actively seeking further collaborations to expand our pipeline. While we remain dedicated to gene therapy and tackling age-related diseases, our goal is to create a diversified research portfolio that can withstand market challenges. This approach is essential for sustainable growth and continued innovation in biotechnology.
Appointed Prof. Dr. Mary E. Rinella, Director, Metabolic and Fatty Liver Disease Department at the University of Chicago. She has investigated a broad range of topics within fatty liver disease, including the use of non-invasive measures to minimize the use of liver biopsy and the study of new therapies to treat fatty liver disease, since there is still no FDA approved treatment. Dr. Rinella has published nearly 150 peer-review articles in prestigious journals, such as Nature Reviews Gastroenterology & Hepatology, Gastroenterology, Hepatology, Journal of the American Medical Association (JAMA), The Lancet and others.
Heading into 2024, Genflow is well placed to take advantage of the recent resurgence of interest in the longevity sector. We continue to monitor opportunities, and to prioritize marketing efforts to expand our investor audience in North America and Europe. Our commitment to innovation and improving lives remains steadfast, as we navigate the opportunities and challenges that lie ahead. Together, we envision a future where our pioneering work redefines possibilities, bringing hope and transformative solutions to those who need it most.
Dr. Eric Leire
Founder and CEO
Genflow Biosciences Plc
January 25, 2024
Key Milestones
Q1 2023: Issued a shareholder update on the Company’s progress, highlighting our expanded intellectual property portfolio through a provisional patent application focusing on the ability to edit the SIRT6 gene, shown to play a role in longevity and age-related diseases as well as our solid cash position.
Q2 2023: Expanded our intellectual property portfolio through a provisional patent application focusing on the ability to edit the SIRT6 gene, shown to play a role in longevity and age-related diseases. If successful, the patent will represent a significant breakthrough in the field of gene editing, with potential implications for longevity and other forms of gene therapy;
Genflow started trading on the OTCQB Venture Market in the US under the ticker GENFF. This move aligns with our strategic emphasis on the US due to its significant advancements in longevity and our ongoing collaborations with US-based institutions;
The Company appointed Prof. Dr. Sven Francque on our Scientific Advisory Board. Prof. Francque is currently Chairman of the Department of Gastroenterology and Hepatology of the University Hospital Antwerp and Full Professor of Medicine at the Faculty of Medicine and Health Sciences of the University of Antwerp in Belgium. He has a longstanding interest and expertise in nonalcoholic fatty liver disease and conducted [basic] research focusing on steatosis. His research unit continues to study pathophysiological mechanisms of NASH. He also conducts clinical research, and his unit is a partner in several research consortia supported by the European Commission.
Q3 2023: Received positive comments from the Federal Agency for Medicines and Health Products (FAHMP) of Belgium regarding the design of our upcoming Phase I/II clinical trials of our lead drug candidate, GF-1002 with patients suffering from NASH. Following our encouraging results from in-vitro human cell and in-vivo rodent studies, the Agency concurred with Genflow’s proposal to commence clinical trials directly with NASH patients, thereby bypassing Phase I trials with healthy volunteers;
Appointed Harbor Access, a strategic Investor Relations firm with offices in the US and Canada to provide investor relations support and investor outreach.
Q4 2023: Appointed Capital Plus Partners Ltd (“CPP”) to act as Joint Broker, alongside Clear Capital Markets Limited. The addition of CPP is expected to bring additional expertise to the Company, strengthen our position and improve access to the capital;
Genflow Biosciences Plc 2023 Year in Review
2023 was a busy and productive year for Genflow Biosciences Plc (“Genflow) marked by significant advancements in our mission to pioneer novel therapeutics for a longer, healthier life. The groundbreaking gene therapies that we are working on alongside our co-collaborators are being engineered to target both the ageing process, and reduce and delay the onset of age-related diseases. Our mission remains to lower healthcare expenditures while easing the emotional and social challenges associated with an ageing population.
We’ve made numerous strategic moves this year as a part of our ongoing efforts to strengthen our company, financial and market position. Our balance sheet remains strong, and we are in a solid financial position. To comply with the updated requirements of the existing grant from the Wallonia region, and to be eligible for future grant funding, we undertook an internal debt re-organization without dilution. This puts us in a favorable financial position compared to many other biotechnology companies.
We diligently continue to pursue the research, development, and safe implementation of our two pivotal programs centered on NASH (Non-Alcoholic Steatohepatitis) and Werner Syndrome and have made significant progress this year.
NASH. We are pleased to report that our NASH program, which afflicts an estimated 35 million individuals worldwide and ranks among the leading causes of chronic liver disease with the urgent need for life-saving liver transplants, is progressing to plan. This program is advancing steadily, underscoring our firm commitment to combatting this pressing global health issue. In collaboration with Dr. Manlio Vinciguerra, (a Genflow Scientific Advisory Board member based at the University of Liverpool), are gaining a significantly deeper understanding of the biochemical changes that occur in the treatment of NASH using the centenarian SIRT6. This research has led to us clearly identifying the workings of our lead drug candidate, GF-1002 and its potential benefits for NASH patients. As a result, we have accumulated important data and filed a new patent application on this specific activity. Additionally, NASH clinical trials are expected to begin in Q1-Q2 2025 following dialogue and subsequent agreement with the European Medicine Agency.
Werner Syndrome.
Simultaneously, we are making progress targeting Werner Syndrome, an accelerated ageing disease. Here, our vision is clear: to enhance the quality of life for affected patients and expedite the path towards swift and successful first-in-human trials under orphan drug designation. Our lead compound GF-3001, is a topical delivery of SIRT6 to the skin.